These drugs, produced by Johnson & Johnson and Roche, are priced significantly high in India—Daratumumab costs over ₹7 lakh per dose, while Atezolizumab is priced around ₹1.5 lakh.

The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.

EU and CN sourced daratumumab. The company is now conducting comparative efficacy studies. For more news like this visit TOI. Get all the Latest News, City News, India News, Business News ...